Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy
- 9 December 2020
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 35 (7) , 2030-2042
Abstract
Most AML patients exhibit mutational activation of the PI3K/AKT signaling pathway, which promotes downstream effects including growth, survival, DNA repair, and resistance to chemotherapy. Herein we demonstrate that the inv(16)/KITD816Y AML mouse model exhibits constitutive activation of PI3K/AKT signaling, which was enhanced by chemotherapy-induced DNA damage through DNA-PK-dependent AKT phosphorylation. Strikingly, inhibitors of either PI3K or DNA-PK markedly reduced chemotherapy-induced AKT phosphorylation and signaling leading to increased DNA damage and apoptosis of inv(16)/KITD816Y AML cells in response to chemotherapy. Consistently, combinations of chemotherapy and PI3K or DNA-PK inhibitors synergistically inhibited growth and survival of clonogenic AML cells without substantially inhibiting normal clonogenic bone marrow cells. Moreover, treatment of inv(16)/KITD816Y AML mice with combinations of chemotherapy and PI3K or DNA-PK inhibitors significantly prolonged survival compared to untreated/single-treated mice. Mechanistically, our findings implicate that constitutive activation of PI3K/AKT signaling driven by mutant KIT, and potentially other mutational activators such as FLT3 and RAS, cooperates with chemotherapy-induced DNA-PK-dependent activation of AKT to promote survival, DNA repair, and chemotherapy resistance in AML. Hence, our study provides a rationale to select AML patients exhibiting constitutive PI3K/AKT activation for simultaneous treatment with chemotherapy and inhibitors of DNA-PK and PI3K to improve chemotherapy response and clinical outcome.Keywords
This publication has 63 references indexed in Scilit:
- Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patientsLeukemia Research, 2013
- The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemiaLeukemia, 2013
- Akt: A Double-Edged Sword in Cell Proliferation and Genome StabilityJournal of Oncology, 2012
- KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in miceBlood, 2012
- Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent mannerExperimental Hematology, 2011
- Gene expression profiling in MDS and AML: potential and future avenuesLeukemia, 2011
- Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancersProceedings of the National Academy of Sciences of the United States of America, 2010
- PKBα/Akt1 Acts Downstream of DNA-PK in the DNA Double-Strand Break Response and Promotes SurvivalMolecular Cell, 2008
- Elucidation of the Phenotypic, Functional, and Molecular Topography of a Myeloerythroid Progenitor Cell HierarchyCell Stem Cell, 2007
- Pluripotent and myeloid-committed CD34+ subsets in hematopoietic stem cell allograftsBone Marrow Transplantation, 2003